The Changing Landscape of Dyslipidemia Management: Focus on PCSK9 Inhibitors

Approximately 121.5 million adults in the United States have cardiovascular disease it is the leading cause of death in this country. The earlier patients begin to follow heart healthy lifestyles and modify risk factors the greater their reduction in overall risk. In this activity an expert lipidologist will review the most recent American College of Cardiology/American Heart Association guidelines on dyslipidemia covering primary prevention as well as secondary prevention in patients with clinical atherosclerotic cardiovascular disease. He will also provide guidance regarding a patient-centered approach to the management of patients with dyslipidemia including lifestyle management and when and how to use high-intensity statins ezetimibe and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.

Share

Program Content

Activities

Focus on PCSK9 Inhibitors
The Changing Landscape of Dyslipidemia Management: Focus on PCSK9 Inhibitors
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: August 31, 2019

Expires: August 29, 2020

Faculty

cover img faculity

Douglas Jacoby, MD

Associate Professor of Clinical Medicine
University of Pennsylvania Health System
Director
Penn Cardiology Preventive Care
Medical Director
Penn Presbyterian Heart and Vascular Pavilion
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

cover img faculity

Mary Knudtson, DNSc, NP, FAAN

Associate Vice Chancellor
Student Health and Wellness
Executive Director
Student Health Services
University of California, Santa Cruz
Santa Cruz, California
Professor of Clinical Nursing
University of California, Irvine
Irvine Irvine, California

 

Provided by

ProCE Banner

Supporters

This activity was developed from a series of programs cosupported by educational grants from

AbbVie

Boehringer Ingelheim

Genentech TEXT Only

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc.

Sanofi US

Shire

Teva